Testing the Effects of Disease‐Modifying Antirheumatic Drugs on Vascular Inflammation in Rheumatoid Arthritis: Rationale and Design of the TARGET Trial

Individuals with rheumatoid arthritis (RA) are at increased risk for atherosclerotic cardiovascular disease (ASCVD) events relative to the general population, potentially mediated by atherosclerotic plaques that are more inflamed and rupture prone. We sought to address whether RA immunomodulators re...

Descripción completa

Detalles Bibliográficos
Autores principales: Giles, Jon T., Rist, Pamela M., Liao, Katherine P., Tawakol, Ahmed, Fayad, Zahi A., Mani, Venkatesh, Paynter, Nina P., Ridker, Paul M., Glynn, Robert J., Lu, Fengxin, Broderick, Rachel, Murray, Meredith, Vanni, Kathleen M. M., Solomon, Daniel H., Bathon, Joan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8207684/
https://www.ncbi.nlm.nih.gov/pubmed/33932148
http://dx.doi.org/10.1002/acr2.11256

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8207684/
https://www.ncbi.nlm.nih.gov/pubmed/33932148
http://dx.doi.org/10.1002/acr2.11256

Ejemplares similares